Abstracts Archive - Page 551 of 2425 - ACR Meeting Abstracts

Abstract Number: 1722 • ACR Convergence 2021
Risk of Pre-eclampsia and Impact of Disease Activity and Anti-rheumatic Treatment in Women with Rheumatoid Arthritis, Axial Spondylarthritis, and Psoriatic Arthritis – A Collaborative Matched Cohort Study from Sweden and Denmark
Anne Emilie Secher¹, Karin Hellgren², Bente Glintborg³, Ane Rom⁴, Merete Hetland⁵ and Fredrik Granath², ¹COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Frederiksberg, Denmark, ²Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ³COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ⁴The Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark, ⁵DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Pre-eclampsia is a pregnancy-related syndrome with potentially fatal outcomes. In RA, high disease activity has been associated to adverse pregnancy outcomes such as preterm…
Abstract Number: 1748 • ACR Convergence 2021
The Peroxisome Proliferator-Activated Receptor-γ (PPAR) Agonist Pioglitazone Improves Vascular and Metabolic Dysfunction in Patients with Systemic Lupus Erythematosus (SLE)
Sarfaraz Hasni¹, Yenealem Temesgen-Oyelakin², Michael Davis³, Sarthak Gupta⁴, Elaine Poncio⁵, Mohammad Naqi¹, Xinghao Wang⁶, Christopher Oliveira⁷, Dillon Claybaugh¹, Amit Dey¹, Shajia Lu¹, Philip Carlucci⁸, Zerai Manna¹, Yinghui Shi¹, Isabel Ochoa⁵, Donald Thomas⁹, Theo Heller¹⁰, Massimo Gadina¹¹, Jun Chu⁴, Monica Purmalek¹, Xiaobai Li¹², Martin Playford¹³, Nehal Mehta¹³ and Mariana Kaplan¹, ¹National Institutes of Health, Bethesda, MD, ²National Institutes of Health (NIH), Bethesda, MD, ³NIAMS, Bethesda, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁵NIH/NIAMS, Bethesda, MD, ⁶NIAMS/NIH, Bethesda, MD, ⁷National Institutes of Health (NIH), Vienna, VA, ⁸New York University School of Medicine, New York, NY, ⁹Arthritis and Pain Associates of Prince George's County, Silver Spring, MD, ¹⁰NIDDK/National Institutes of Health, Bethesda, MD, ¹¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ¹²Clinical Center, National Institutes of Health, Bethesda, MD, ¹³NHLBI/National Institutes of Health, Bethesda, MD
Background/Purpose: Premature cardiovascular events in SLE are associated with significant mortality and morbidity with no effective treatments described to date. Both immune dysregulation characteristics of…
Abstract Number: 1750 • ACR Convergence 2021
Itolizumab, a Novel anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-escalation Study
Kenneth Kalunian¹, Richard Furie², Jai Radhakrishnan³, Vandana Mathur⁴, Krishna Polu⁴, Stephen Connelly⁴, Joel Rothman⁴, Cherie Ng⁴, Leslie Chinn⁵, Maple Fung⁶, Dolca Thomas⁷ and Chaim Putterman⁸, ¹UC San Diego, La Jolla, CA, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Columbia University, New York, NY, ⁴Equillium, Inc., La Jolla, CA, ⁵Equillium, Inc., South San Francisco, CA, ⁶Equillium, Inc., San Diego, CA, ⁷Equillium, Inc., Brooklyn, NY, ⁸Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: CD6, a co-stimulatory receptor predominantly expressed on T cells, promotes CD4+ T cell proliferation and differentiation into Th1/Th17 cells. The CD6 ligand, activated leukocyte…
Abstract Number: 1749 • ACR Convergence 2021
Treatment Patterns in Latin American Patients with Lupus Nephritis over a 20-year Period
Rosana quintana¹, Jose Gomez Puerta², Guillermina Harvey³, Marina Scolnik⁴, Nidia Meras⁵, Cintia Otaduy⁶, Maria Salinas⁷, Valeria Arturi⁸, Maria Sattler⁹, Rosa Serrano Morales¹, Luciana Gonzalez Lucero¹⁰, Wilfredo Grageda¹¹, Nicolas Perez¹², Cecilia Nora Pisoni¹³, Simone Appenzeller¹⁴, Ana Silva¹⁵, Odirlei Andre Monticielo¹⁶, Henrique Moriz¹⁷, Francinne Ribiero¹⁸, Emily Figueiredo Neves Yuki Yuki¹⁹, Edgard Neto²⁰, Iris Guerra²¹, Paula Burgos²², Milena Mimica²³, Gustavo Aroca²⁴, Gabriel Tobon²⁵, Luis Gonzalez²⁶, Gerardo Quintana-López²⁷, Andres Bonfanti²⁴, RAFAEL LOPEZ²⁸, Luis Jara Quezada²⁹, Margarita Portela-Hernandez³⁰, HILDA FRAGOSO LOYO³¹, Luis H Silveira³², Ignacio Garcia-De La Torre³³, Carlos Abud-Mendoza³⁴, Jorge Esquivel-Valerio³⁵, Jonathan Losanto³⁶, Astrid Paats³⁷, JORGE CIEZA CALDERON³⁸, Manuel Ugarte-Gil³⁹, Katiuzka Zuniga Corrales⁴⁰, Roberto Munoz⁴¹, Ernesto Cairoli⁴², Gonzalo Silveira⁴³, Luis Catoggio⁴⁴, Ashley Orillion⁴⁵, Chetan Karyekar⁴⁶, Federico Zazzetti⁴⁷ and Bernardo A. Pons-Estel⁴⁸, ¹Grupo Oroño. Centro Regional de Enfermedades Autoinmunes y Reumaticas (GO-CREAR), Rosario, Argentina, ²Hospital Clinic, University of Barcelona, Barcelona, Spain, ³Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Italiano de Córdoba, Córdoba, Argentina, ⁶Hospital Córdoba, Cordoba, Argentina, ⁷Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁸Hospital HIGA San Martín, La Plata, Argentina, ⁹Sanatorio Británico, Cordoba, Argentina, ¹⁰Janssen Cilag Farmaceutica SA, Tucuman, Argentina, ¹¹Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ¹²Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, ¹³CEMIC, Buenos Aires, Argentina, ¹⁴Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, ¹⁵UFG, GOIANIA, Goias, Brazil, ¹⁶Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁷Hospital das Clinicas, Universidade Federal de Pernambuco, Pernambuco, Brazil, ¹⁸Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, ¹⁹Hospital Das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil, ²⁰UNIFESP, São Paulo, Brazil, ²¹Hospital del Salvador, Santiago, Chile, ²²Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile, ²³Universidad San Sebastián, Santiago, Chile, ²⁴Clínica de la Costa Ltda., Barranquilla, Colombia, ²⁵Fundación Valle del Lili, Cali, Colombia, ²⁶Universidad de Antioquia, Medellin, Colombia, ²⁷Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital; Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia; Department of Internal Medicine, School of Medicine, Universidad de Los Andes, Bogota, Colombia, ²⁸Hospital Luis Vernaza, Guayaquil, Ecuador, ²⁹Centro Médico La Raza, Mexico City DF, Mexico, ³⁰IMSS, Mexico Df, Mexico, ³¹INCMNSZ, Tlalpan, Mexico, ³²Instituto Nacional de Cardiologia, Mexico City, Mexico, ³³Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, ³⁴Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatología y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ³⁵University Hospital Dr. Jose Eleuterio Gonzalez, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³⁶Hospital de Clínicas I, San Lorenzo, Paraguay, ³⁷Hospital de Clinicas, Asuncion, Paraguay, ³⁸Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ³⁹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ⁴⁰Hospital Cayetano Heredia, Lima, Peru, ⁴¹Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, ⁴²Autoimmune Diseases Unit, Centro Asistencial del Sindicato Médico del Uruguay (CASMU) and Hospital Evangélico, Montevideo, Uruguay, ⁴³Hospital Señor del Milagro, Salta, Argentina, ⁴⁴Hospital Italiano de Buenos Aires, Olivos, Argentina, ⁴⁵Global Commercial Strategic Organisation, Johnson and Johnson, Horsham, PA, ⁴⁶Janssen R&D, Spring House, PA, ⁴⁷Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, ⁴⁸Grupo Oroo - Centro Regional de Enfermedades Autoinmunes y Reumticas (GO-CREAR), Rosario, Argentina
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease. Over the last decade, changes have occurred in the treatment of these patients,…
Abstract Number: 1753 • ACR Convergence 2021
Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease Activity and Improvements in Cardiovascular Risk Factors
Laurence Magder¹, Michelle Petri² and Daniel Goldman², ¹University of Maryland, Baltimore, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: In SLE, treatment with hydroxychloroquine (HCQ) has been shown to be associated with reduced SLE flares and reduced risk of damage in several different…
Abstract Number: 1756 • ACR Convergence 2021
Class V Systemic Lupus Erythematosus Nephritis Patients Are Undertreated and Face Similar Adverse Renal Outcomes as Class III/IV Patients
April Barnado and Alex Camai, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Few studies have investigated treatment patterns and renal outcomes in class V systemic lupus erythematosus (SLE) nephritis patients compared to class III/IV patients. Prior…
Abstract Number: 1755 • ACR Convergence 2021
Increasing Participation of Underrepresented Groups in Lupus Clinical Trials: Insights from Qualitative Interviews with Patients and Physicians
Saira Sheikh¹, Maria Naylor², Becky Lane², Jennifer Sacks², Janine Gaiha-Rohrbach² and Cherie Butts², ¹University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ²Biogen, Cambridge, MA
Background/Purpose: Systemic lupus erythematosus disproportionately affects Black/African American (AA) and Latino/a populations.1 Challenges to engage and include these populations in clinical trials (CTs) can be…
Abstract Number: 1744 • ACR Convergence 2021
Improvement of Renal and Non-Renal SLE Outcome Measures on Sirolimus Therapy – a 21-year Follow-up Study of 73 Patients
Paramarajan Piranavan¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: The clinical heterogeneity of the SLE makes it often challenging for the treating clinician and also remains one of the many reasons behind failed…
Abstract Number: 1729 • ACR Convergence 2021
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus (SLE) Using 2nd Trimester Estimated Glomerular Filtration Rate (eGFR)
Anika Lucas¹, Amanda Eudy¹, Michelle Petri², Rebecca Fischer-Betz³, Abeer Nabil⁴, Cecilia Nalli⁵, Laura Andreoli⁶, Angela Tincani⁷, Yair Molad⁸, Stephen Balevic¹ and Megan Clowse⁹, ¹Duke University, Durham, NC, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Uniklinik Dsseldorf, Dsseldorf, Germany, ⁴University of Cairo, Cairo, Egypt, ⁵ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁶University of Brescia, Brescia, Italy, ⁷ASST Spedali Civili-University of Brescia, Gussago, Italy, ⁸Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, ⁹Duke University, Chapel Hill, NC
Background/Purpose: Women with SLE are at increased risk for adverse maternal and fetal outcomes with increased odds of preeclampsia, hypertension, Cesarean and preterm deliveries, low…
Abstract Number: 1728 • ACR Convergence 2021
Takayasu’s Arteritis and Pregnancy: A Meta-analysis
Aine Gorman¹, Leah Rooney², Matthew Turk¹, Louise Moore³, Jared Bierbrier⁴, Celine O'Brien⁵, Anne Clohessy⁶, Eamonn Molloy⁷, Lorraine O Neill⁸, Fionnuala McAuliffe⁹ and Douglas Veale¹⁰, ¹St Vincents Hospital, Dublin, Ireland, ²St Vincent's University Hospital, Dublin, Ireland, ³Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Kinnegad, Ireland, ⁴McMaster University, Hamilton, ON, Canada, ⁵Perinatal Research Centre, Obstetrics and Gynaecology, School of Medicine, University College Dublin and National Maternity Hospital, Dublin, Dublin, Ireland, ⁶National Maternity Hopistal, Dublin, Ireland, ⁷St Vincent's Healthcare Group, Dublin, Ireland, ⁸St. Vincent's Hospital, Dublin, Ireland, ⁹National Maternity Hopsital Dublin, Dublin, Ireland, ¹⁰University College Dublin, Dublin, Ireland
Background/Purpose: Takayasu’s arteritis is a systemic autoimmune disease characterised by large vessel vasculitis. It usually affects women of childbearing age, with 90% of patients diagnosed…
Abstract Number: 1754 • ACR Convergence 2021
Effect of Belimumab on Autoantibodies, Complement, and B-Cell Subsets in Patients with Lupus Nephritis
Brad Rovin¹, Richard Furie², Ana Malvar³, Cynthia Aranow⁴, Jose M Pego-Reigosa⁵, Elena Zakharova⁶, Andreas Schwarting⁷, Angela Jones-Leone⁸, Anuradha Madan⁸, Jennifer Gilbride⁹, David Roth⁸, Yulia Green⁹ and André van Maurik¹⁰, ¹Ohio State University Wexner Medical Center, Columbus, OH, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Hospital Fernandez, Buenos Aires, Argentina, ⁴Feinstein Institutes for Medical Research, Manhasset, NY, ⁵Complexo Hospitalario Universitario de Vigo, Hospital Meixoeiro, Galicia Sur Health Research Institute, Rheumatology Department and IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Vigo, Spain, ⁶Moscow City Clinical Hospital n.a. S.P. Botkin, Moscow, Russia, ⁷University Center of Autoimmunity, Mainz, Germany, ⁸GlaxoSmithKline, Collegeville, PA, ⁹GlaxoSmithKline, Brentford, United Kingdom, ¹⁰GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Lupus nephritis (LN) is a complication affecting ~40% of patients with systemic lupus erythematosus (SLE). Belimumab (BEL), an anti–B-lymphocyte stimulator therapy, was approved in…
Abstract Number: 1714 • ACR Convergence 2021
Exploring the Sexual and Reproductive Health (SRH) Needs of Men with Rheumatic Diseases
Olivia Stransky¹, Nicole Hunt², John Richards³ and Mehret Birru Talabi¹, ¹University of Pittsburgh, Pittsburgh, PA, ²UPMC, Pittsburgh, PA, ³Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA
Background/Purpose: Few studies have comprehensively evaluated the information needs and priorities that men with rheumatic diseases have about their sexual and reproductive health (SRH). This…
Abstract Number: 1727 • ACR Convergence 2021
Behcet’s Disease: A Meta-analysis of Pregnancy Outcomes
Leah Rooney¹, Aine Gorman², Matthew Turk³, Louise Moore⁴, Celine O'Brien⁵, Jared Bierbrier⁶, Anne Clohessy⁵, Eamonn Molloy⁷, Lorraine O Neill⁸, Fionnuala M. Mc Auliffe⁵ and Douglas Veale⁹, ¹St Vincent's University Hospital, Dublin, Ireland, ²St Vincents Hospital, Dublin, Ireland, ³St. Vincents University Hospital, Dublin, Ireland, ⁴Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Kinnegad, Ireland, ⁵Perinatal Research Centre, Obstetrics and Gynaecology, School of Medicine, University College Dublin and National Maternity Hospital, Dublin, Dublin, Ireland, ⁶McMaster University, Hamilton, ON, Canada, ⁷St Vincent's Healthcare Group, Dublin, Ireland, ⁸St. Vincent's Hospital, Dublin, Ireland, ⁹University College Dublin, Dublin, Ireland
Background/Purpose: Behcet’s disease is a systemic inflammatory disease which commonly presents with episodes of acute inflammation, oral and genital ulcers, uveitis and skin lesions. It…
Abstract Number: 1730 • ACR Convergence 2021
Disease Activity and Outcome in Pregnancies of Patients with SpA – Data from the German Pregnancy Register RHEKISS
Anja Weiß¹, Christina Bungartz¹, Jutta Richter², Susanna Späthling-Mestekemper³, Xenofon Baraliakos⁴, Peer Aries⁵, Rebecca Fischer-Betz⁶ and Anja Strangfeld⁷, ¹DRFZ, Berlin, Germany, ²Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ³Rheumapraxis München, München, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ⁵Rheumatologie in Hamburg, Hamburg, Germany, ⁶Uniklinik Dsseldorf, Dsseldorf, Germany, ⁷Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Background/Purpose: SpA is a severe chronic inflammatory disease, which affects quality of life and functional status. It frequently occurs in women of childbearing age. Active…
Abstract Number: 1743 • ACR Convergence 2021
Whole Blood Hydroxychloroquine Levels Do Not Correlate with QTc Intervals in a Cohort of 84 SLE Patients: Evidence That Antimalarials Are Not Associated with Cardiac Conduction System Toxicity
Mayce Haj-Ali¹ and H. Michael Belmont², ¹NYU Grossman School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug used in the treatment of systemic lupus erythematous (SLE). There is limited data assessing cardiac toxicity as arrhythmias…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].